Tradestie Institutional Equity Comparison Engine

MRNA vs GMAB โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

MRNA Overall Edge

MRNA Captures Institutional Edge (2โ€“2 Pillars ยท 5โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Moderna, Inc. Common Stock (MRNA) driven by superior Valuation, Momentum & Technical while GMAB counters with relative strength in Growth & Margin, Options & Structure. Fundamentally, MRNA trades at 23.0x Forward P/E with -80.8% operating margin (+29.2% YoY revenue) versus GMAB at 29.3x Forward P/E and 30.6% operating margin (+16.1% YoY). In options structure, MRNA sits in CONSOLIDATION (52nd %ile IV; Dealer Gamma Walls on Pro) against GMAB sits in UNCLASSIFIED (9th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner MRNA
MRNA 23.0x vs GMAB 29.3x Fwd P/E
Growth & Margin Winner GMAB
Op Margin -80.8% vs 30.6% ยท YoY +29.2% vs +16.1%
Momentum & Technical Winner MRNA
1Y +706.5% vs +65.5% ยท 52W Pos 67% vs 74%
Options & Structure Winner GMAB
CONSOLIDATION (52nd %ile IV) vs UNCLASSIFIED (9th %ile IV)
MRNA NASDAQ
Moderna, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$195.00
-2.17% 1D
Market Cap $80.7B
1M Return -3.77%
1Y Return +706.45%
Forward P/E 23.0x
Unified AI Score
40.3 / 100 SELL
Tech 18.0 Fund 42.0 Flow 67.0 Mom 46.0
GMAB NASDAQ
Genmab A/S ADS
Pharmaceutical Preparations
$50.60
-1.46% 1D
Market Cap $31.7B
1M Return +26.5%
1Y Return +65.52%
Forward P/E 29.3x
Unified AI Score
40.1 / 100 SELL
Tech 15.0 Fund 36.0 Flow 50.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: MRNA +706.45% GMAB +65.52% Spread: +640.93 pp (MRNA Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
MRNA TTM Op. Margin: -80.8% GMAB TTM Op. Margin: 30.6%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MRNA vs GMAB. Trailing 12-month operating profitability (MRNA -80.8% vs GMAB 30.6%) and valuation multiples (MRNA 23.0x vs GMAB 29.3x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: MRNA (5) vs GMAB (4)
Institutional Metric MRNA GMAB Criterion Row Winner
Market Capitalization Scale $80.7B $31.7B Larger Scale MRNA
Trailing P/E Ratio Valuation 23.0x 43.9x Lower Multiple MRNA
Forward P/E Ratio Valuation 23.0x 29.3x Lower Multiple MRNA
Revenue Growth (YoY) Growth +29.2% +16.1% Higher Growth MRNA
Operating Margin (TTM) Profitability -80.8% 30.6% Higher Margin GMAB
Net Profit Margin Profitability -110.5% 17.0% Higher Margin GMAB
Return on Equity (ROE) Capital Efficiency -34.5% 12.1% Higher ROE GMAB
52-Week Range Position Momentum 67% ($22โ€“$281) 74% ($24โ€“$60) Stronger Trend GMAB
Beta / 30D Volatility Risk Regime 2.23ฮฒ ยท 78% Vol 0.71ฮฒ ยท 106% Vol Lower Realized Risk MRNA
Unified Institutional Score Composite Signal 40.3 / 100 (SELL) 40.1 / 100 (SELL) Higher Composite Tie

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full MRNA vs GMAB Buy Guide
MRNA CONSOLIDATION
22d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 52nd %ile
IV Regime Balanced (25thโ€“60th %ile)
Live MRNA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
GMAB UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 9th %ile
IV Regime Compressed (<25th %ile)
Live GMAB Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither MRNA nor GMAB registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.